TY - CHAP
T1 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy
AU - Van den Bergh, P. Y.K.
AU - Hadden, R. D.M.
AU - Bouche, Pierre
AU - Cornblath, D. R.
AU - Hahn, A.
AU - Illa, I.
AU - Koski, C. L.
AU - Léger, J. M.
AU - Nobile-Orazio, E.
AU - Pollard, J.
AU - Sommer, C.
AU - van Doorn, P. A.
AU - van Schaik, I. N.
PY - 2010/9/6
Y1 - 2010/9/6
KW - Aim to update EFNS/PNS guideline on management of CIDP-based on newly available evidence
KW - Chronic inflammatory demyelinating polyradiculoneuropathy
KW - Dearth of evidence, concerning general aspects of treatment for symptoms of CIDP-as pain and fatigue
KW - Demyelinating polyradiculoneuropathy-and electrodiagnostic criteria
KW - Different sets of diagnostic criteria for CIDP-sensitivity and specificity varying
KW - Good Practice Points for defining diagnostic criteria for CIDP-initial management
KW - Immunosuppressant and immunomodulatory drugs-beneficial in CIDP (Class IV evidence)
KW - Intravenous immunoglobulin-showing that IVIg 2.0 g/kg produces significant improvement in disability lasting 2-6 weeks
KW - No evidence-based guideline-as none of trials, systematically assessed long-term management
KW - Supportive features for diagnosis of CIDP-macrophage-associated demyelination, onion bulb formation, demyelinated and remyelinated nerve fibres
UR - http://www.scopus.com/inward/record.url?scp=84885489018&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/9781444328394.ch20
DO - https://doi.org/10.1002/9781444328394.ch20
M3 - Chapter
SN - 9781405185332
VL - 1
SP - 333
EP - 341
BT - European Handbook of Neurological Management
PB - Wiley-Blackwell
ER -